8.73
2.71%
+0.23
Coya Therapeutics Inc stock is currently priced at $8.73, with a 24-hour trading volume of 46,926.
It has seen a +2.71% increased in the last 24 hours and a +5.95% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $8.42 pivot point. If it approaches the $8.93 resistance level, significant changes may occur.
Previous Close:
$8.50
Open:
$8.5
24h Volume:
46,926
Market Cap:
$127.62M
Revenue:
-
Net Income/Loss:
$-12.36M
P/E Ratio:
-6.5812
EPS:
-1.3265
Net Cash Flow:
$-11.39M
1W Performance:
+6.33%
1M Performance:
+5.95%
6M Performance:
+63.18%
1Y Performance:
+51.56%
Coya Therapeutics Inc Stock (COYA) Company Profile
Name
Coya Therapeutics Inc
Sector
Industry
Phone
800-587-8170
Address
5850 San Felipe Street, Suite 500, Houston
Coya Therapeutics Inc Stock (COYA) Latest News
Chardan Capital Reiterates Coya Therapeutics (COYA) Buy Recommendation - MSN
MSN
How Hop On A Cure Foundation is helping to say goodbye to ALS - KHOU.com
KHOU.com
Treg Cell-Based Therapies Pipeline Analysis, 2024 Updates | Latest FDA, EMA, and PMDA Approvals - openPR
openPR
Where are the Opportunities in (COYA) - Stock Traders Daily
Stock Traders Daily
Coya Therapeutics, Inc.'s (NASDAQ:COYA) largest shareholders are retail investors with 60% ownership, insiders own ... - Yahoo Finance
Yahoo Finance
EF Hutton Reiterates Coya Therapeutics (COYA) Buy Recommendation - MSN
MSN
Coya Therapeutics Inc Stock (COYA) Financials Data
Coya Therapeutics Inc (COYA) Net Income 2024
COYA net income (TTM) was -$12.36 million for the quarter ending September 30, 2023, a -14.81% decrease year-over-year.
Coya Therapeutics Inc (COYA) Cash Flow 2024
COYA recorded a free cash flow (TTM) of -$11.39 million for the quarter ending September 30, 2023.
Coya Therapeutics Inc (COYA) Earnings per Share 2024
COYA earnings per share (TTM) was -$1.2511 for the quarter ending September 30, 2023, a +12.94% growth year-over-year.
About Coya Therapeutics Inc
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an allogeneic Treg exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company was incorporated in 2020 and is headquartered in Houston, Texas.
Cap:
|
Volume (24h):